Susquehanna Fundamental Investments LLC Takes Position in Twist Bioscience Corporation $TWST

Susquehanna Fundamental Investments LLC bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, Holdings Channel reports. The firm bought 34,189 shares of the company’s stock, valued at approximately $3,517,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TWST. Royal Bank of Canada increased its holdings in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after buying an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after acquiring an additional 3,181 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after purchasing an additional 37,577 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $737,000.

Insider Activity

In other news, SVP Paula Green sold 291 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the transaction, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. The trade was a 0.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 41,570 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the completion of the transaction, the chief executive officer directly owned 770,729 shares in the company, valued at approximately $117,135,393.42. The trade was a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 193,099 shares of company stock valued at $24,026,581. 3.08% of the stock is owned by company insiders.

Twist Bioscience Trading Down 1.7%

Shares of TWST opened at $139.00 on Tuesday. The business’s 50-day moving average price is $108.03 and its 200-day moving average price is $74.64. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $155.44. The stock has a market cap of $8.72 billion, a PE ratio of -62.61 and a beta of 2.14. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same period in the previous year, the company posted $0.33 earnings per share. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Canaccord Genuity Group boosted their target price on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Piper Sandler upped their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 24th. Finally, Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average target price of $98.30.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.